This trial is testing a new vaccine for people with glioblastoma. The goal is to see if it is safe and if it helps people live longer.
1 Primary · 2 Secondary · Reporting Duration: Two years
24 Total Participants · 4 Treatment Groups
Primary Treatment: TH-1 Dendritic Cell Immunotherapy · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: